Akari Therapeutics raises CEO Gaslightwala's base salary to $625,000 from $475,000 and bonus target to 55%

Akari Therapeutics Plc

Base salary raised from $475,000 to $625,000 effective Aug 18, 2026; $562,500 paid in cash and $62,500 delivered as RSUs over the 12 months beginning Aug 18, 2026.
Target annual bonus lifted to 55% of base salary from 50%, for total target salary-plus-bonus of about $970,000, calculated on the full $625,000 base.
174,000 ADS options granted under the 2023 Equity Incentive Plan effective Aug 18, 2026, vesting monthly over four years with vesting deemed to begin March 18, 2026.
RSUs vest in four quarterly installments from Nov 18, 2026 to Aug 18, 2027; RSUs and the 174,000 options are forfeited if shareholders do not approve a 2023 Plan ADS reserve increase.
Amendment also restates the CEO agreement's existing equity: 1,100,000 ADS time-based option and 600,000 ADS performance option tied to Dec 31, 2025 financing or licensing milestones.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.